Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/11/2025

Management of COPD Patients with Bullae

Pharmacologic Therapy

  • The American College of Physicians recommends inhaled bronchodilators as first-line therapy for stable COPD patients with respiratory symptoms and FEV1 <60% predicted 1, 2
  • Monotherapy using either long-acting inhaled anticholinergics or long-acting inhaled β-agonists is recommended for symptomatic COPD patients with FEV1 <60% predicted 2
  • Choice of specific monotherapy should be based on patient preference, cost, and adverse effect profile 2

Pulmonary Rehabilitation

  • Pulmonary rehabilitation improves health status and dyspnea in patients with FEV1 <50% predicted 3
  • For COPD patients with bullae, standard pulmonary rehabilitation without incentive spirometry is safer and still effective 4

Oxygen Therapy

  • Supplemental oxygen reduces mortality rates among symptomatic patients with resting hypoxemia 3, 5
  • Long-term oxygen therapy shows a reduction in mortality for patients with severe resting hypoxemia 1

Management Options for Bullae in COPD

  • Bullectomy may be considered for patients with giant bullae (occupying >1/3 of hemithorax) surrounded by relatively normal parenchyma 6
  • Lung Volume Reduction Surgery (LVRS) should be considered for patients with upper-lobe predominant emphysema and low exercise capacity 6
  • Patients with homogeneous emphysema and good exercise capacity should not undergo LVRS due to higher mortality risk 6
  • LVRS is contraindicated in patients with FEV1 ≤20% predicted with either homogeneous emphysema on HRCT or DLCO ≤20% predicted 6

Important Considerations for COPD Management

  • Spirometry should be obtained to diagnose airflow obstruction in patients with respiratory symptoms but should not be used to screen for airflow obstruction in individuals without respiratory symptoms 1, 7
  • All current smokers should receive smoking cessation counseling and be offered pharmacologic therapies to increase cessation rates 7
  • All patients 50 years of age or older should be offered influenza vaccine annually 7